MediciNova Initiates Phase II Trial for Moderate-to-Severe Asthma Patients

MediciNova has started dosing in a Phase II clinical trial of MN-221 for patients with moderate-to-severe, but stable, asthma.

After enrolling 15–25 patients, this second Phase II trial will determine the safety and efficacy of the drug to help prevent asthma attacks.

The company said it hopes the drug will have fewer cardiovascular side effects that are often observed with similar agents. An intravenous formulation of MN-221 has been developed to bypass constricted airways and deliver effective concentrations of the drug to the lungs.